Dentsply Sirona (XRAY) Stock Looks Cheap On Sales Yet Weak On Cash Flow

DENTSPLY SIRONA stock has seen a steep share price decline over the past few years, yet the current valuation checks point to a company that screens cheap on several measures. With the share price recently at US$11.43, the question for you is whether the weak long term share performance is already reflected in today’s valuation.

• Over the past 5 years the stock has fallen 79.6%, which leaves current investors assessing whether sentiment has swung too far to the downside.
• The key potential support for the valuation is the ability of DENTSPLY SIRONA to convert its dental equipment and consumables revenue into consistent cash flow. A major risk is that any pressure on margins or capital spending needs could limit that cash generation.
• The broader checks lean cheap, with the company screening as undervalued on most metrics, and a value score of 6 that points to a generally supportive valuation profile.

The issue now is whether DENTSPLY SIRONA’s current market price already reflects the operational risks, or whether the valuation still leaves enough room for a meaningful recovery in returns.

Compare DENTSPLY SIRONA’s depressed 5 year return with other stocks that screen as inexpensive on quality and valuation by scanning 52 high quality undervalued stocks in minutes.

Is DENTSPLY SIRONA Still Cheap on Sales?

The P/S multiple is often a useful cross check for DENTSPLY SIRONA because revenue can sometimes be more stable than earnings for equipment and consumables focused companies. On this measure, the stock currently trades on a P/S of 0.6x. That is below the Medical Equipment industry average P/S of 2.9x and also below the peer group average of 4.3x.

The tailored fair P/S ratio for DENTSPLY SIRONA, which adjusts for factors such as its size, risk profile and typical margins, is 1.3x. Against the current 0.6x P/S, the market is pricing the shares at roughly half of that reference point. For you as an investor, that highlights a wide gap between the sales multiple implied by this model and the level at which the stock currently trades.

On the P/S multiple, DENTSPLY SIRONA stock appears inexpensive relative to both its industry and the fair ratio benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The DENTSPLY SIRONA Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for DENTSPLY SIRONA help connect this valuation puzzle to clear scenarios for the company’s future by spelling out which paths for revenue growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price on the Community page. Each narrative links its number to a concrete view of how growth, profitability and risks might evolve, which you can revisit as fresh information emerges.

DENTSPLY SIRONA attracts sharply different views right now, with some investors focused on resilience and others focused on execution and industry headwinds.

Bull case: 75% undervalued

"One of XRAY’s strengths is its consumables portfolio, products that practices reorder regularly regardless of capital spending cycles..."

Read the full Bull Case to see why DENTSPLY SIRONA could be undervalued

Bear case: 9% overvalued

"Ongoing legacy fallout from previous accounting scandals and governance issues may continue to lead to higher legal expenses, diminished stakeholder trust, and sustained elevated SG&A costs..."

Read the full Bear Case to see why DENTSPLY SIRONA could be overvalued

Do you think there's more to the story for DENTSPLY SIRONA? Head over to our Community to see what others are saying!

The Bottom Line

DENTSPLY SIRONA screens as undervalued on market multiples, with current pricing implying a meaningful discount to its tailored sales benchmark and sector peers. That discount only becomes attractive if the company can sustain cash generation from its dental equipment and consumables business while managing margin and capital spending pressures. For you, the key question is whether current concerns around governance history, legal costs and execution risk are already embedded in the price. The crux of the bull versus bear debate is whether DENTSPLY SIRONA can deliver stable profitability that eventually encourages a re rating, rather than the current discount proving to be a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com